Adjuvant Targeted Therapy for Stage IB EGFR-Mutant NSCLC: Advances and Perspectives
10.3760/cma.j.cn112434-20250218-00042
- VernacularTitle:ⅠB期EGFR突变NSCLC辅助靶向治疗临床研究进展
- Author:
Yu LIU
1
;
Shengxiang REN
;
Gening JIANG
Author Information
1. 同济大学附属上海市肺科医院胸外科，上海 200433
- Publication Type:Journal Article
- From:
Chinese Journal of Thoracic and Cardiovascular Surgery
2025;41(8):508-512
- CountryChina
- Language:Chinese
-
Abstract:
Stage ⅠB non-small cell lung cancer (NSCLC), a potentially curable malignancy, continues to exhibit a substantial recurrence rate post-surgery. Targeted therapy has significantly improved the prognosis of patients with advanced epidermal growth factor receptor mutation (EGFRm), while the need and optimal timing for adjuvant targeted therapy in epidermal growth factor receptor mutant (EGFRm) stage ⅠB patients remain unclear. This review systematically examines the advancements of adjuvant targeted therapy in stage ⅠB EGFRm NSCLC and critically explores the practical problems in its clinical application. Third-generation targeted agents, such as Osimertinib, have significantly improved disease-free survival in stage ⅠB EGFRm NSCLC according to the seventh edition of the TNM staging system. However, the survival benefits in this population based on the eighth/ninth edition staging systems have yet to be fully validated, and stage ⅠB NSCLC patients exhibit different treatment response patterns. Consequently, current research focuses on high-risk subgroups to optimize treatment outcomes. Major clinical challenges include acquired resistance, determining the optimal treatment timing, and implementing individualized treatment strategies. Future research should concentrate on elucidating the mechanisms of resistance, optimizing treatment timing, establishing precise risk stratification systems, and exploring personalized treatment strategies guided by dynamic monitoring of circulating tumor DNA. This review aims to provide a comprehensive analysis of these key issues and offer a theoretical foundation for optimizing the clinical practice of adjuvant targeted therapy in stage ⅠB NSCLC.
